2026-01-22 - Analysis Report
**1. Company Overview**
Amgen is a biotechnology company that develops and manufactures medicines, including oncology, inflammation, and cardiovascular therapies.

**2. Return Rate Comparison**
- Ticker: AMGN
- Compare to S&P 500 (VOO)
- Cumulative Return of AMGN: 77.83%
- Cumulative Return of VOO: 91.55%
- Divergence: -13.72% (difference in cumulative return on the last day of the data)

**3. Cumulative Return Analysis**
- The cumulative return of AMGN is lower than that of VOO.
- The relative divergence indicates that the current position is at the top 17.9% percentile of past data.

**4. Recent Stock Price Fluctuations**
- Latest Close: $343.60
- 5-day SMA: $332.80
- 20-day SMA: $330.28
- 60-day SMA: $325.94
- Price fluctuation: The stock has had a sharp rebound from the previous close.

**5. RSI, PPO Index Indicators, and Delta_Previous_Relative_Divergence**
- Market Risk Indicator (MRI): 0.80
- RSI: 61.26
- PPO: 0.27
- Hybrid Signal: Buy
- Risk Level: Medium
- Recent Relative Divergence Change: 4.00 (+): improving
- 7-day Rank Change: 26 (+): rank up
- 7-day Dynamic Expected Return Change: 0.10 (+): improving
- Expected Return (%): -2.00%

**6. Recent News & Significant Events**
- AMGEN INC (NASDAQ:AMGN) Shows High Technical and Setup Ratings for Potential Breakout
- Arkadios Wealth Advisors Increases Stock Holdings in Amgen Inc. $AMGN
- Amgen Inc. (AMGN) has announced that it will be increasing its dividend to $2.52
- Amgen (AMGN) Expands Obesity Strategy With Ro Collaboration on GLP-1 Therapies

**7. Analyst Opinions**
- Analyst Consensus:
  - Key: Buy
  - Mean (1=StrongBuy~5=Sell): 2.41 (~Buy)
  - Opinions: 27
  - Target Price (avg/high/low): 331.59 / 425.00 / 180.00

**8. Recent Earnings Analysis**
| Date | EPS | Revenue |
|---|---:|---:|
| 2025-11-05 | 5.98 | 9.56 B$ |
| 2025-08-06 | 2.66 | 9.18 B$ |
| 2025-05-02 | 3.22 | 8.15 B$ |
| 2024-10-31 | 5.27 | 8.50 B$ |
| 2025-11-05 | 5.27 | 8.50 B$ |

- Earnings Per Share (EPS) has been generally increasing over the past year.
- Revenue has also increased, with the exception of the 2025-05-02 quarter.

**9. Financial Information - 5. Revenue and Profitability**
| Quarter | Revenue | Profit Margin |
|---------|----------|---------------|
| 2025-09-30 | $9.56B | 67.75% |
| 2025-06-30 | $9.18B | 67.20% |
| 2025-03-31 | $8.15B | 63.58% |
| 2024-12-31 | $9.09B | 65.75% |
| 2024-09-30 | $8.50B | 61.07% |

- Revenue and profit margin have generally increased over the past year.

**10. Financial Information - 5. Capital and Profitability**
| Quarter | Equity | ROE |
|---------|---------|-----|
| 2025-09-30 | $9.62B | 33.43% |
| 2025-06-30 | $7.43B | 19.28% |
| 2025-03-31 | $6.21B | 27.87% |
| 2024-12-31 | $5.88B | 10.67% |
| 2024-09-30 | $7.53B | 37.60% |

- Equity has generally increased over the past year.
- Return on Equity (ROE) has also increased, with some fluctuations.

**Comprehensive Analysis**
Amgen has generally performed well in terms of revenue and profit margins. The stock has had a sharp rebound in price, but the cumulative return is lower than that of the S&P 500. The RSI and PPO indicators suggest a medium risk level, and the expected return is negative. The recent news and events suggest positive developments for the company. Overall, the stock's performance is mixed, and further analysis is needed to determine its potential for long-term investment.

**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.